Dr. Kazandjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1120 NW 14th St
Rm 828
Miami, FL 33136Phone+1 305-243-5001
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2003 - 2006
Boston University School of MedicineClass of 2003
Certifications & Licensure
VA State Medical License 2004 - 2026
FL State Medical License 2020 - 2025- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Clinical Trials
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry Start of enrollment: 2022 Jul 01
Roles: Contact
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Sep 27
Roles: Contact
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Start of enrollment: 2023 Mar 26
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsGenomic Classification and Individualized Prognosis in Multiple Myeloma.Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, Alexandra M Poos, Andriy Derkach
Journal of Clinical Oncology. 2024-04-10 - 28 citationsThe mutagenic impact of melphalan in multiple myelomaFrancesco Maura, Niels Weinhold, Benjamin Diamond, Dickran Kazandjian, Leo Rasche
Leukemia. 2021-05-19 - 456 citationsMultiple myeloma epidemiology and survival: A unique malignancy.Dickran Kazandjian
Seminars in Oncology. 2016-12-01
Abstracts/Posters
- Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to DisagreeDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple MyelomaDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition - Tip SheetNovember 13th, 2024- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024
- Sylvester Pursues Landmark Research Presented at International Hematology ConferenceJanuary 30th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
